Efficient lysis of CD44v7/8-presenting target cells by genetically engineered cytotoxic T-lymphocytes - A model for immunogene therapy of cervical cancer

Gynecologic Oncology

Volumn 66, Issue 2, 1997, Pages 209-216

  Dall, P ^a   Hekele, A ^b   Beckmann, M W ^b   Bender, H G ^b   Herrlich, P ^b   Ponta, H ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HERMES ANTIGEN; HYBRID PROTEIN; INTERLEUKIN 2; RECOMBINANT PROTEIN; T LYMPHOCYTE RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EXON; GENE TRANSFER; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION; TARGET CELL; UTERINE CERVIX CANCER;

EID: 0031214664     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4777     Document Type: Article

References (30)

1. Chen I, Ashe S, Brady W A, Hellstrom I, Hellstrom K E, Ledbetter J A, Mcgowan P, Linsley P S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 71:1992;1093-1102.
2. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan R C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 90:1993;3539-3543.
3. Hwu P, Yannelli J, Kriegler M, Perez C, Chiang Y, Schwarz S, Cowherd R, Delgado C, Mulé J, Rosenberg S A. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-α DNA for the gene therapy of cancer in humans. J Immunol. 150:1993a;4104-4115.
4. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells. J Immunol. 150:1993;1458-1470.
5. Rosenberg S A, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 233:1986;1318-1320.
6. 8+. Science. 259:1993;368-370.
7. Fanger M W, Segal D M, Romet-Lemonne J-L. Bispecific antibodies and targeted cellular cytotoxicity. Immunol Today. 12:1991;51-54.
8. Wolf H, Freimann U, Jung G. Target cell induced T cell activation with bispecific antibodies: a new concept for tumor immunotherapy. Recent Results Cancer Res. 135:1994;185-195.
9. Jain R K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 50:1990;814s-819s.
10. Dall P, Heider K-H, Hekele A, von Minckwitz G, Kaufmann M, Ponta H, Herrlich P. Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res. 54:1994;3337-3341.
11. Dall P, Hekele A, Ikenberg H, Göppinger A, Bauknecht T, Pfleiderer A, Moll J, Hofmann M, Ponta H, Herrlich P. Increasing incidence of CD44v7/8 epitope expression during uterine cervical carcinogenesis. Int J Cancer. 69:1996;79-85.
12. Weiss A, Littman D R. Signal transduction by lymphocyte antigen receptors. Cell. 76:1994;263-274.
13. Marcucci F, Waller M, Kirchner H, Krammer P. Production of immune interferon by murine t-cell clones from long-term cultures. Nature. 291:1981;79-81.
14. Miller A D, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol. 6:1986;2895-2902.
15. Morgenstern J P, Land H. Advanced mammalian gene transfer: high titer retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:1990;3587-3596.
16. Rozdzial M M, Kubo R T, Turner S L, Finkel T H. Developmental regulation of the TCR z-chain. differential expression and tyrosine phosphorylation of the TCR z-chain in resting immature and mature T lymphocytes. J Immunol. 153:1994;1563-1580.
17. Weissman A M, Baniyash M, Hou D, Samelson L E, Burgess W H, Klausner R D. Molecular cloning of the zeta-chain of the t cell antigen receptor. Science. 239:1988;1018-1021.
18. Hekele A, Dall P, Moritz D, Wels W, Groner B, Herrlich P, Ponta H. Growth retardation of tumors by adoptive transfer of cytotoxic T-lymphocytes reprogrammed by CD44v6-specific scfv:ζ-chimera. Int J Cancer. 68:1996;232-238.
19. Wels W, Beerli R, Hellmann P, Schmidt M, Marte B M, Kornilowa E S, Hekele A, Mendelsohn J, Groner B, Hynes N E. EGF receptor and p185 erbB2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer. 60:1995;137-144.
20. Zamoyska R, Vollmer A C, Sizer K C, Liaw C W, Parnes J R. Two lyt-2 polypeptides arise from a single gene by alternative splicing patterns of mRNA. Cell. 43:1985;153-163.
21. Miller A D, Rosman G J. Improved retroviral vectors for gene transfer and expression. Biotechniques. 7:1989;980-990.
22. Kabat E A, Wu T T, Perry H M, Gottesman K S, Foeller C. Sequences of Proteins of Immunological Interest. 1991;U.S. Dept. Health Human Services, Washington.
23. Irving B A, Weiss A. The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways. Cell. 64:1991;891-901.
24. Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for erbb2 expressing tumor cells. Proc Natl Acad Sci. 91:1994;4318-4322.
25. Moritz D, Groner B. A spacer region between the single-chain antibody and the CD3 z-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther. 2:1995;539-546.
26. Sherman L, Sleeman J, Dall P, Hekele A, Moll J, Ponta H, Herrlich P. The CD44 Proteins in Embryonic Development and in Cancer. Current Topics In Microbiology and Immunology. 1996;Springer Verlag, Berlin. p. 249-269.
27. Altenschmidt U, Kahl R, Moritz D, Schnierle B S, Gerstmayer V, Wels W, Groner B. Cytolysis of tumor cells expressing the Neu/erbB2, erbB3, and erbB4 receptor by genetically targetted naive T lymphocytes. Clin Cancer Res. 2:1996;1001-1008.
28. Zentilin L, Tafuro S, Grassi G, Garcia R, Ventura A, Baralle F, Falaschi A, Giacca M. Exp Cell Res. 15:1996;257-267.
29. Brocker T, Karjalainen K. Signals through the T-cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 181:1995;1653-1659.
30. Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trümper L, Hartmann F, Diehl V, van Lier R, Pfreundschuh M. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science. 264:1994;833-835.